AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03249974 — intervention group
Intervention type: DEVICE
Intervention: Enlite sensor communicating with Minimed 640G pump
Description: Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
Study NCT03033082 — intervention group
Intervention type: OTHER
Intervention: Questionnaire sheets
Description: A- Marital satisfaction Index (MSI). Interview (Modified Arabic translation)~B- Sexual Satisfaction Scale:(SSS). The Arabic version of the sexual satisfaction scale was used.~C- International Index of Erectile Function Questionnaire (IIEF-5): For male subjects.~D- The Eysenck Personality Questionnaire (EPQ):~The Arabic version of the EPQ was used.
Study NCT02213744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Study NCT02213744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT02133820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg 12 hourly capsule - strong pain killer fasted
Study NCT03043859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pure Prairie Living Program
Description: Education session (n=5) on healthy eating, menu planning and skill building for effective diabetes management
Study NCT01106664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-7746
Description: 1mg, 2mg, 4mg, 8mg, 16mg, once daily for multiple-dose study; 4mg at a single dose for food effect study.
Study NCT01106664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7746
Description: 1mg, 2mg, 4mg, 8mg, 16mg once daily for multiple-dose study; 4mg at a single dose for food effect study
Study NCT03340363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: environmental change
Description: 1. Offer kid-friendly, low-cost recipes in a prominent, high-traffic location.~2. Offer healthy default ingredients (bundled ingredients promoted with recipes).~3. Promote recipe ingredients with prominently displayed signage and images.~4. Promote recipes in multiple locations throughout the store.
Study NCT03340363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: messaging
Description: Short, behavioral messages sent to participants via text message or email each week to promote the in-store environmental changes
Study NCT04644822 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F] PSMA-1007 Injection
Description: a novel \[18F\] PSMA radiotracer that is highly selective for PSMA.
Study NCT00968786 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Home monitoring
Description: automated measuring devices for patients using at home
Study NCT03564444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent influenza vaccine
Description: A single dose of bivalent vaccine (10\^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1.
Study NCT03564444 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
Study NCT02133820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg 12 hourly capsule - strong pain killer fed
Study NCT02636426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: In new dosing schedule of sorafenib is investigated in this study: high-dose, pulsatile sorafenib
Study NCT02562105 — intervention group
Intervention type: PROCEDURE
Intervention: Mechanical ventilation
Description: requiring mechanical ventilation at admission to ICU for one day or more during the study period
Study NCT03320200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CNS-focused treatment
Description: The CNS-focused treatment will last for 10 weeks, conducted in 60-minute sessions on a weekly basis. In addition, participants in this group will complete a home treatment program for 30 minutes, five times a week.
Study NCT03320200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care Treatment
Description: The standard physiotherapy group will receive a 10-session treatment program that will include one corticosteroid infiltration provided in the early acute stage followed by a multimodal physiotherapy program including analgesic modalities (e.g. TENS, cryotherapy) and exercise and manual therapy techniques addressing the specific mobility deficits of each patient. This program also include a home treatment based on conventional physiotherapy that involves a training load comparable to that in the CNS-focused group.
Study NCT00128830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Description: Participants will receive 800 mg of ETR (2 x 4 tablets of formulation TF035) twice daily and after the formulation switch they will receive 200 mg of ETR (2 x 2 tablets of formulation F060) twice daily until the participants benefitted from etravirine or it became comercially available.
Study NCT00128830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleotide reverse transcriptase inhibitors (NRTIs)
Description: Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
Study NCT00128830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protease inhibitors (PIs)
Description: Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
Study NCT00128830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF)
Description: Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
Study NCT00388076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3
Study NCT00388076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib in combination with pazopanib and paclitaxel in Part 3
Study NCT00388076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: in combination with pazopanib
Study NCT00388076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: in combination with pazopanib
Study NCT01248689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: concentration profile 1
Description: IOP will be measured under this order of sevoflurane concentrations:~7%, 5%, 2%, 0.5%
Study NCT01248689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: concentration profile 2
Description: IOP will be measured under this order of sevoflurane concentrations:~7%, 2%, 5%, 0.5%
Study NCT01248689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: concentration profile 3
Description: IOP will be measured under this order of sevoflurane concentrations:~7%, 0.5%, 5%, 2%
Study NCT00987389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded and the blood cells are returned to the body with a plasma substitute.
Study NCT00987389 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Plasma Exchange
Description: No plasma exchange.
Study NCT00987389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids [Standard Dose]
Description: During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a standard regimen.
Study NCT00987389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids [Standard Dose]
Description: During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a standard regimen.
Study NCT00987389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids [Reduced Dose]
Description: During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a reduced regimen.
Study NCT00987389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids [Reduced Dose]
Description: During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a reduced regimen.
Study NCT02521935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Complete traditional dentures
Description: Arm 1-Standard Treatment Sequence for Traditional Removable Dentures in a Dental School Clinic (9 Appointments):~Appointment 1: Examination \& diagnosis \& initial impressions.~Appointment 2: Secondary impressions.~Appointment 3: Secondary or definitive impressions (Often 2 appointments are needed to border mold and impression)~Appointment 4: Maxillo-mandibular jaw relation records (both centric and vertical relation). Tooth selection.~Appointment 5: Wax-trial denture try-in.~Appointment 6: Insertion and instructions for care of definitive prostheses.~Appointments 7-9 Post adjustments
Study NCT02521935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Complete CADCAM dentures
Description: Arm 2-Standard Treatment Sequence for Digital Dentures in a Dental School Clinic (5 appointments):~Appointment 1: Exam, diagnosis, \& tray selection (begin impressions)~Appointment 2: Definitive impressions and Maxillomandibula relations~Appointment 3: Wax-trial arrangement~Appointment 4: Insertion and instructions for care of definitive prosthesis~Appointment 5: Post adjustment/s (Less post insertion adjustments are anticipated due to CADCAM milling of the denture base and less polymerization shrinkage
Study NCT02908282 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: REMOGEN OMEGA
Description: Lubricant eye drops: preservative-free, hypotonic microemulsion of polyunsaturated fatty acids and hydrating polymers provided in single-dose containers of 0.25 ml.
Study NCT02908282 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Povidone
Description: Artificial tears: preservative-free eye drops containing 2% povidone.
Study NCT03979781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tailored antiplatelet selection
Description: antiplatelet selection guided by platelet function phenotype and/or key pharmacogene genotypes
Study NCT03979781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: antiplatelet selection using standard of care
Study NCT03524989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: 40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 2 months.
Study NCT03524989 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM treatment
Description: 40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week for 2 months.
Study NCT03918694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Daily use of Vit C tablets
Study NCT03918694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily use of placebo tablets
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160Eu/0.5ml in infants (6-11 months old)
Description: inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320Eu/0.5ml in infants (6-11 months old)
Description: inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640Eu/0.5ml in infants (6-11 months old)
Description: inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1280Eu/0.5ml (without adjuvant) in infants (6-11 months old)
Description: inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0Eu/0.5ml in infants (6-11 months old)
Description: 0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160Eu/0.5ml in infants (12-23 months old)
Description: inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320Eu/0.5ml in infants (12-23 months old)
Description: inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640Eu/0.5ml in infants (12-23 months old)
Description: inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1280Eu/0.5ml (without adjuvant) in infants (12-23 months old)
Description: inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
Study NCT01512706 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0Eu/0.5ml in infants (12-23 months old)
Description: 0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
Study NCT02133820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 hourly capsule strong painkiller with antagonist fasted)
Study NCT02133820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg 12 hourly capsule strong painkiller with antagonist fed
Study NCT03443661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
Study NCT04140331 — intervention group
Intervention type: DEVICE
Intervention: Accelerometer
Description: Patient will wear the accelerometer for 7 consecutive days to measure the level of physical activity.
Study NCT02548806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine MBT 50µg
Description: Clonidine MBT 50µg, single dose
Study NCT02548806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine MBT 100µg
Description: Clonidine MBT 100µg, single dose
Study NCT02548806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Catapres 100μg
Description: Catapres tablet 100μg, single dose
Study NCT02851667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resident training programs
Description: A total of 24 resident training programs such as talks, day camp and thematic activities were delivered in the intervention estate by CFSC from June to November 2011. Each program included an introduction to the concepts of Learning Family and family 3Hs as well as how to promote family 3Hs through learning and communicating with family, delivered by interactive games and workshops.
Study NCT06229301 — intervention group
Intervention type: PROCEDURE
Intervention: AI-predicted Nomogram
Study NCT00639860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OSSIX-Plus
Description: resorbable collagen membrane
Study NCT04290572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin capsules
Description: Jelly capsules of isotretinoin
Study NCT02548910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: A central venous catheter will be inserted for every patient to measure central venous pressure, as is the standard of care in elective liver surgery. Strict aseptic technique will be maintained. A total volume of whole blood of 7-10 mL per kg of body weight will be removed, as tolerated. The volume of removed blood will not be replaced by intravenous fluid administration. Collected blood will be transfused back at the end of the liver parenchymal transection, or within 8 hours of collection.
Study NCT02548910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Citrated whole blood collection bag
Description: Transfusion Medicine will send the requested number of whole blood collection bags labelled with the patient's name and MRN. These whole blood collection bags are used in standard practice for collection of whole blood.
Study NCT04513769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegan diet
Description: Participants will receive a behavioral intervention on a vegan diet in partnership with a local vegan soul food restaurant
Study NCT01901484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel
Description: All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.
Study NCT01650948 — intervention group
Intervention type: DEVICE
Intervention: RetnaGene AMD LDT
Study NCT02727816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: filcon IV I (BC 8.6)
Description: control lens
Study NCT02727816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: filcon IV I (BC 8.7)
Description: control lens
Study NCT02727816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ocufilcon D
Description: test lens
Study NCT02727816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: methafilcon A (BC 8.6)
Description: control lens
Study NCT02727816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: methafilcon A (BC 8.7)
Description: control lens
Study NCT02727816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: test lens
Study NCT02832102 — intervention group
Intervention type: PROCEDURE
Intervention: Standard treatment of SCCHN patients
Description: The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.
Study NCT03069833 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis
Description: computer-aided diagnosis to assist colonoscopists
Study NCT02826408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole sodium
Description: WIll study effect of the medication on palpittions
Study NCT02826408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pacebo
Description: Placebo comparison to active treatment
Study NCT03857932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Participants receive SLNB as well as non SLNs resection
Description: Participants only receive SLNB preoperative CT lymphography SLNB with stained non-SLN resection SLNB with ARM dissection
Study NCT00923351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor Purged/CD25 Depleted Lymphocytes
Study NCT00923351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
Description: Tumor lysate/KLH pulsed dendritic cells (minimum of 1 X 10e6 cells/kg) on Day2.
Study NCT00923351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-7
Description: rhIL-7 (20 mcg/kg/dose SQ) approx. 48 hours prior to vaccine) Day 0, Day 14, Day 28 and Day 42
Study NCT00923351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine
Description: Tumor lysate/KLH Pulsed dendritic cell vaccine (1-5 X 10e7 cells/injection site, given in 3 sites intradermal) on Day 2, Day 16, Day 30, Day 44, Day 56, Day 70.
Study NCT00532311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and stable statin therapy
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.
Study NCT00532311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stable statin therapy
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
Study NCT03619577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential training
Description: For cognitive training, the BrainHQ program, self-made teaching aids and board games will be used to train different cognitive functions of the participants. For physical exercise, we design the programs that involve balance or strength training components in the aerobic exercises. All participants will first perform 60 minutes of physical exercise followed by 60 minutes of cognitive training.
Study NCT03146663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-1031 500 mg
Description: NUC-1031 500 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
Study NCT03146663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-1031 750mg
Description: NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle